Abstract: Methods and kits for diagnosing arthritis are provided. The methods may involve detection of 14-3-3 eta or gamma proteins in a sera or synovial fluid sample.
Type:
Grant
Filed:
May 6, 2020
Date of Patent:
June 27, 2023
Inventors:
Aziz Ghahary, Wolodymyr Walter Peter Maksymowych, Ruhangiz Taghi Kilani
Abstract: The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
Abstract: The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N?-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.
Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
June 20, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
Abstract: Provided are oil-in-water microemulsions for formulating pharmaceutically active compounds. The microemulsions contain oils, surfactants, water, and the pharmaceutical compounds, and are produced by mixing an aqueous phase and a lipid phase in which each phase contains at least one surfactant in a defined ratio whereby the resulting microemulsion has very small dispersed particles and is thermodynamically very stable.
Type:
Grant
Filed:
March 19, 2021
Date of Patent:
June 13, 2023
Assignees:
SIFI S.p.A., Consiglio Nazionale delle Ricerche
Inventors:
Elena Solfato, Ilenia Abbate, Cristina Maria Concetta Zappulla, Manuela Santonocito, Santa Viola, Sandro De Falco, Francesco Giuliano
Abstract: Provided herein are compositions and methods for treating pulmonary arterial hypertension. In particular, provided herein are dry powder formulations of TMP for delivery to the lung.
Type:
Grant
Filed:
October 25, 2018
Date of Patent:
June 6, 2023
Assignee:
Arizona Board of Regents on Behalf of the University of Arizona
Inventors:
Heidi M. Mansour, Jason Yuan, Jian Wang, Alexan I. Gomez, Priyardarshini Muralidharan, Yali Gu
Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Abstract: This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
Abstract: Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.
Type:
Grant
Filed:
December 30, 2019
Date of Patent:
May 30, 2023
Assignees:
Guangdong Provincial Hospital of TCM, The Second Affiliated Hospital Of Guangzhou University of Chinese Medicine, The Second Clinical College Of Guangzhou University of Chinese Medicine, Guangdong Provincial Academy Of Chinese Medical Sciences
Inventors:
Bo Liu, Xianzhang Huang, Zhimin Yang, Jun Li, Quanfu Chen, Liqiao Han, Hualun Liang, Yiqi Yang, Kai Wang, Xiaowan Wang, Ennian Li, Yi Wang, Runyue Huang, Yunshan Wu, Xiaodong Han, Jinlang Zhong, Bidan Zheng
Abstract: This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
Type:
Grant
Filed:
January 25, 2021
Date of Patent:
May 23, 2023
Assignees:
Novartis AG, Palobiofarma S.L.
Inventors:
Kai Cui, Julio Cesar Castro-Palomino Laria, Weiyong Kong
Abstract: This disclosure relates to methods and compositions with enhanced levels of one or more tyramine containing hydroxycinnamic acid amides. Also disclosed herein are methods for producing a consumable product with enhanced levels of a tyramine containing hydroxycinnamic acid amide. Some embodiments relate to a composition enriched with a tyramine containing hydroxycinnamic acid.
Type:
Grant
Filed:
November 12, 2021
Date of Patent:
May 16, 2023
Assignee:
Brightseed, Inc.
Inventors:
Lee Heil Chae, James Flatt, Alexandra Marcela Herrmann, Gabriel Navarro, Jessica Leigh Ochoa
Abstract: In certain embodiments, this disclosure relates to KRAS agonists, pharmaceutical composition, and uses in managing cancer. In certain embodiments, the KRAS agonist is 4-(4-(2-bromoacetamido)butyl)benzoic acid, salt, prodrug, or derivative thereof. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of a compound of Formula I, salt, prodrug, or derivative thereof, to a subject in need thereof, wherein, substituents are reported herein.
Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands.
Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
May 9, 2023
Assignees:
Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S
Abstract: Provided herein are methods of treating cancer in a subject, wherein the cancer is extrachromosomal DNA-positive (ecDNA-positive) or therapeutically resistant, the method comprising administering to the subject a therapeutically effective amount of a replication stress (RS) pathway agent alone or in combination with a targeted therapeutic.
Type:
Grant
Filed:
October 21, 2022
Date of Patent:
May 9, 2023
Assignee:
BOUNDLESS BIO, INC.
Inventors:
Christian Hassig, Ryan Hansen, Snezana Milutinovic, Jason Christiansen, Zachary Hornby, Sudhir Chowdhry, Anthony Celeste, Kristen Turner, Deepti Wilkinson
Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
Type:
Grant
Filed:
February 14, 2022
Date of Patent:
April 25, 2023
Assignee:
ALNYLAM PHARMACEUTICALS, INC.
Inventors:
Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan